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SUMMARY
Background—Limitations of the current annual influenza vaccine have led to ongoing efforts to
develop a “universal” influenza vaccine, i.e., one that targets a ubiquitous portion of the influenza
virus so that the coverage of a single vaccination can persist for multiple years.
Objectives—To estimate the economic value of a “universal” influenza vaccine compared to the
standard annual influenza vaccine, starting vaccination in the pediatric population (2–18 year
olds), over the course of their lifetime.
Patient/methods—Monte Carlo decision analytic computer simulation model
Results—Universal vaccine dominates (i.e., less costly and more effective) the annual vaccine
when the universal vaccine cost ≤$100/dose and efficacy ≥75% for both the 5 and 10 year
duration. The universal vaccine is also dominant when efficacy is ≥50% and protects for 10 years.
A $200 universal vaccine was only cost-effective when ≥75% efficacious for a 5 year duration
when annual compliance was 25% and for a 10 year duration for all annual compliance rates. A
universal vaccine is not cost-effective when it cost $200 and when its efficacy is ≤50%. The cost-
effectiveness of the universal vaccine increases with the duration of protection.
Conclusions—Although development of a universal vaccine requires surmounting scientific
hurdles, our results delineate the circumstances under which such a vaccine would be a cost-
effective alternative to the annual influenza vaccine.
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The following limitations of the current annual influenza vaccine have led to ongoing efforts
to develop a “universal” influenza vaccine, i.e., one that targets a ubiquitous portion of the
influenza virus so that the coverage of a single vaccination can persist for multiple years:
• Annual vaccine administration: Administering influenza vaccine to the same
patients each year incurs substantial costs and efforts. Persons must miss work.
Maintaining influenza vaccination clinics and sites requires personnel time.
• Annual vaccine manufacturing: Every year influenza vaccine manufacturers must
allocate significant resources to produce influenza vaccines. Due to varying viral
strains every season and the limited production period, the timing and preparation
of vaccine development might cause unnecessary delays.
• Patient compliance: Even when a person is recommended to be vaccinated, he or
she may miss getting immunized certain years. According to the National Health
Interview Survey and National Immunization Survey of United States for seasons
2005–2006, 2006–2007, and 2007–2008 and National Immunization Survey,
influenza vaccination coverage levels ranged 31.8%–32.2% for ages 6–23 months,
26.4%–40.3% for ages 2–4 years, and 12.4%–21.1% for ages 5–17 years.[1]
Estimation from the Behavioral Risk Factor Surveillance System (BRFSS) for
influenza season 2008–2009 was 26.0%–38.7% for ages 2–4 year olds and 18.4%–
23.4% for ages 5 to 17 year olds.[2]
• Changing influenza strains: Each year, different influenza strains emerge as the
dominant circulating strains. Although each year, scientists attempt to predict these
strains, their predictions are not always accurate.[3] Mutations may cause major
antigenic drift every 2 to 5 years.[4]
• Emergence of novel influenza strain: As the 2009 influenza pandemic
demonstrated, the annual vaccine may not cover new emergent strains.
Better understanding of the potential economic value of a “universal” vaccine can help guide
investment and development for policy makers, manufacturers, insurance companies,
investors, scientists, and other decision makers. Forecasting the impact of a vaccine early in
its development when changes can still be made can increase the chances of a vaccine's
success.[5]
Objectives
We developed a computational model to estimate the potential economic value of a
“universal” influenza vaccine compared to the standard annual influenza vaccine in the
pediatric population (ages 2 to 18 years), one of the Advisory Committee on Immunization
Practices (ACIP) recommended high risk groups.[6]
Patients/methods
Model Structure
Figure 1 presents the general structure of the Markov decision analytic computer simulation
model constructed using TreeAge Pro 2009 (TreeAge Software, Williamstown,
Massachusetts). The model represents the decision from the societal perspective of whether
a child (age 2 to 18 years old) should begin receiving a hypothetical universal influenza
vaccine or the standard annual influenza vaccine The universal vaccine would have a certain
duration of protection, therefore necessitating a periodic booster, and is assumed to be a
single immunization. Each year the individual is scheduled to receive a vaccine, the
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individual had a probability of complying. Additionally, we looked at the effects of
vaccinating high-risk children. For these scenarios we assumed individuals were high-risk
throughout their lifetime and had a twofold risk of hospitalization and mortality.
The time horizon for the model is the child's lifetime. The model has a cycle length of 1
year. The Markov states are mutually exclusive; an individual can only be in one state in a
given year. Each year, an individual had a probability of becoming infected with influenza.
Vaccination attenuates this probability by the vaccine-related efficacy. Each time an
individual is vaccinated, he or she has a probability of developing vaccine side effects.[7]
Individuals who contract influenza have probabilities of developing symptoms or remaining
asymptomatic. Symptomatic individuals then have a probability of visiting an outpatient
setting and a probability of requiring hospitalization. Each individual with influenza has a
probability of surviving or dying from influenza. Those who die from influenza or other
unrelated causes enter the death state. The model concludes its run when an individual enters
this state, otherwise known as the absorptive state.
Each simulation run sends 1,000 individuals 1,000 times through the model for a total of
1,000,000 trials of an individual's lifetime. For each simulation, the following equation
calculates the incremental cost-effectiveness ratio (ICER) of the “universal” vaccine versus
the annual vaccine:
where effectiveness is expressed in quality-adjusted life-years (QALYs). ICER values less
than $50,000 per quality-adjusted life-year (QALY) identified the strategy as cost-effective.
[8–9] The model was from the societal perspective, and therefore accounted for both direct
(i.e., outpatient and hospitalization costs) and indirect costs (i.e., cost of productivity losses
due to missed work (e.g., parent losses for child care) and influenza-attributable mortality of
expected lifetime earnings).
Budget Impact Analysis
We also calculated the potential economic value of a universal influenza vaccine from the
societal perspective for the U.S. pediatric population. The U.S. Census bureau estimate in
July 2009 was used to provide the age stratified population: 21.3 million (under 5 years),
20.6 million (5–9 years), 20.0 million (10–14 years), and 21.5 million (15–19 years).[10]
Data Inputs
Table 1 lists the probabilities, costs, durations, and utilities used in the model along with
their corresponding distributions and sources. Costs of annual vaccination are based on the
average whole sale price and administration cost.[11] Mortality values are from the CDC
National Vital Statistics Reports of Number of Deaths and Death Rates, by Age, Race, and
Sex: United States 2007.[12] A 3% discount rate converted costs and QALYs from other
years into 2010 values.[13] Death resulted in a QALY loss based on the QALY-adjusted life
expectancy of the person's age.[14] Each influenza episode resulted in age-adjusted QALY
decrements for the duration of the condition.[8]
Sensitivity Analyses
Sensitivity analyses systematically varied the cost of the universal vaccine ($100, $200),
universal vaccine efficacy (range: 50%–75%), probability of influenza infection being
symptomatic (50% or 67%), initial age of the individual (range: 2–18 years), compliance
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with annual vaccine (range: 25%, 50%, 75%, and 100%), and the duration of universal
vaccine protection (5 or 10 years).[15–16] Probabilistic sensitivity analyses simultaneously
varied the values of each parameter across the ranges listed in Table 1.
Results
Cost Effectiveness Analysis when Universal Protection Duration is 5 years
Table 2 shows how the ICER of universal vaccination compares to annual vaccination
varying with differing universal vaccine efficacy, cost, and annual vaccine compliance when
the duration of universal vaccine protection is 5 years. Universal vaccine is the dominant
strategy (i.e., saves costs and provides health benefits) when vaccine cost is ≤$100/dose and
vaccine efficacy is ≥75% for all scenarios tested. The annual vaccine dominates the $100
universal vaccine, only when the universal is 50% efficacious and annual compliance is
100%. When increasing the cost to $200/dose, universal vaccine is cost-effective only when
annual compliance is ≤25% and universal vaccine efficacy ≥75% for both symptomatic
rates. A $200 universal vaccine with an efficacy ≤50% was not cost-effective for any annual
compliance rate. For high-risk children, a $100 universal vaccine dominated the annual
vaccine or had ICER values ≥$185,060/QALY for all probabilities of annual compliance.
Budget Impact Analysis when Universal Protection Duration is 5 years
Switching from the annual vaccine to the universal vaccine can yield cost savings from the
societal perspective. A $100/dose universal vaccine with a vaccine efficacy ≥75% will
provide cost savings per pediatric patient vaccinated: $1–$104 (ages below 5 years), $5–
$102 (5–9 years), $6–$96 (10–14 years), and $168–$266 (15–18 years). Therefore,
switching the entire pediatric population to universal vaccination could generate cost savings
of $15 million - $2.2 billion for those below 5 years, $101 million - $2.1 billion for 5–9
years, $121 million - $1.9 billion for 10–14 years, and $3.6 billion - $5.7 billion for 15–18
years over their lifetimes. Increasing the proportion of developing symptomatic influenza
from 50% to 67% will provide more cost savings.
Cost Effectiveness Analysis when Universal Protection Duration is 10 years
Table 3 demonstrates the incremental cost-effectiveness ratio when duration of protection by
the universal vaccine increases from 5 to 10 years. Universal vaccine is optimal (i.e.,
economically dominant) compared to annual vaccine when its efficacy ≥50% and cost ≤
$100/dose for all annual compliance and symptomatic rates explored.
Figure 2 shows acceptability curves for the universal and annual vaccine when the universal
protects for 10 years and costs $100. The universal vaccine consistently has a higher
probability of being cost-effective, even with an increasing willingness to pay. A $200/dose
universal vaccine is cost-effective only when its efficacy is ≥75%. At an efficacy of 50%, a
$200 universal vaccine is not cost-effective compared to the annual vaccine. Figure 2b
shows the curves for this change in cost.
Budget Impact Analysis when Universal Protection Duration is 10 years
Increasing the duration of universal protection to 10 years further augments the potential
cost savings to society. A $100/dose universal vaccine with ≥75% efficacy can provide cost
savings of $295 – $398 per pediatric patients (ages below 5 years), $284 – $388 (5–9 years),
$274 – $377 (10–14 years), and $261–$364 (15–18 years) vaccinated. Therefore, switching
the entire pediatric population to universal vaccination could generate cost savings of $6.2
billion - $8.5 billion for those below 5 years, $5.9 billion - $8.0 billion for 5–9 years, $5.5
billion - $7.5billion for 10–14 years, and $5.6 billion - $7.8 billion for 15–18 years over
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their lifetimes. As before, increasing the probability of being symptomatic will provide even
more cost savings.
Discussion
Our results suggest that a universal vaccine could provide substantial economic value by
overcoming the annual vaccine's current drawbacks. This favors investment in universal
vaccine development, helps establish efficacy and duration of protection targets for
developers, and prepares policy makers for reimbursement questions. Addressing these
issues early in a vaccine's development when changes are easier to make could help avoid
considerable problems in the future.[5]
In many ways, our study underestimates the potential value of a universal vaccine. Not only
is compliance with the annual vaccine far less than 100%, many children do not get
vaccinated until later into the influenza season, i.e., after October or even November. As
previous studies have demonstrated the value of annual influenza vaccine drops the later in
the season the vaccine is administered, because the longer the patient remains unvaccinated,
the more susceptible they are to being infected.[17–18] Moreover, our model did not
account for how the universal vaccine may prevent the vaccinated individual from
transmitting the influenza virus to others. Unvaccinated individuals are not only more
susceptible to infection but may shed more virus when infected compared to vaccinated
individuals. Our model focuses on the individual and does not consider influenza
transmission and herd immunity. If the universal vaccine were to results in a greater
proportion of the populations protected, then it could more substantially reduce transmission
than the standard annual vaccine and therefore would be more cost effective. Finally, in our
model, individuals are healthy children without co-morbidities that may worsen influenza
outcomes.
The 2009 influenza pandemic identifies another possible benefit of the universal vaccine. A
universal vaccine that provides protection against novel strains may circumvent the need to
develop a specific vaccine against an emerging pandemic strain. As computer simulation
studies have suggested, timely and effective vaccination of the population may be the most
important mitigation intervention.[17–20]
Bringing a universal vaccine to market requires surmounting numerous hurdles. First, the
vaccine must contain an appropriate antigen common to all possible circulating influenza
viruses. Second, the antigen should be stable and not prone to mutation. Third, the antigen
must not occur in other common human tissues. Fourth, the antigen needs to generate an
adequate immune response. Fifth, the vaccine must remain effective and not wane for the
duration of vaccine coverage.
Du and colleagues describe the possible approaches in developing a universal influenza
vaccine which focus on the conserved sequences of M2e, HA (HA1, HA2), NP, and
epitopes from different influenza viral proteins.[21] These sequences occur across many
known subtypes of influenza virus making them ideal universal vaccine targets. Some
candidates use a combination of these conserved epitopes from different viral proteins,
potentially offering further cross-protection across varying subtypes.[21] Other candidates
focus on the sequences of major structural proteins of the virus surface, ectodomain of
matrix protein 2.[22–23] Scientists have also targeted human antibodies that could cross-
react with and neutralize several different hemagglutinin viral subtypes.[24–27] Several
candidate “universal” influenza vaccines are currently at different stages of development
based on these targets. Five companies, Acambis Inc. (Cambridge, UK), Cytos
Biotechnology (Schlieren, Switzerland), Merck & Co Inc. (NJ,USA), and VaxInnate Corp.
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(NJ,USA) have reported promising preliminary Phase 1 clinical study results.[3, 28]
BiondVax's (Ness Ziona, Israel) Mulitmeric-001 Universal Flu Vaccine successfully
navigated through phase I/II trials and will enter Phase II trials in 2010.[29–30] BiondVax is
currently recruiting patients 55 to 75 years old for its next study.[31]
A recently published article reports significant human B cell responses towards the 2009
pandemic H1N1 influenza.[32] Most of the neutralizing antibodies induced by the virus are
able to cross-react against epitopes in the hemagglutinin head and stalk of various influenza
strains. Tested antibodies show broad protection against H1N1 and H5N1 influenza strain
with abundantly stalk-reactive antibodies in H1N1 patients. Such universal vaccine may
have a stronger cross-protection to divergent virus subtypes, reduced production time and
cost. This advantage may serve as an important direction in the development of a universal
influenza vaccine.
Another study provides evidence that a universal vaccine which covers all influenza strains
is achievable. This novel influenza vaccine is able to reactivate and induce T-cell responses
(CD8+ and CD4+) towards NP and M1 proteins of the virus that is common in all influenza
type A strains.[33] It proves to be safe and well tolerated with less local side effects.
Extensive protection against seasonal and pandemic influenza is promising. According to
researchers, introduction of such a vaccine would provide protection for at least 5–10 years.
[34]
Limitations
In addition to the limitations identified earlier, all models are simplifications of real life. A
model cannot represent all possible influenza outcomes and the heterogeneity that exist
among the patient population. Rather than make decisions, a model provides information for
decision makers such as public health officials, scientists, insurance companies, investors,
manufacturers, and clinicians. Models are designed to elucidate relationships, raise
questions, and approximate orders of magnitude instead of providing exact answers.
Although our model does not explicitly represent natural immunity from infection, which
may persist for several years, especially when occurring in children, the various outcome
probabilities (e.g., risk of influenza) did draw from studies where natural immunity was
present.
Conclusion
Limitations of the current annual influenza vaccine have led to ongoing efforts to develop a
“universal“ influenza vaccine, i.e., one that targets a conserved portion of the influenza virus
so that the coverage of a single vaccination can persist for multiple years. Our results
suggest that a universal vaccine could provide substantial economic value by overcoming
the annual vaccine's current drawbacks. This favors investment in universal vaccine
development, helps establish efficacy and duration of protection targets for developers, and
prepares policy makers for reimbursement questions. Addressing these issues early in a
vaccine's development when changes are easier to make could help avoid considerable
problems in the future. Although development of a universal vaccine requires surmounting
scientific hurdles, our results delineated the circumstances under which such a vaccine
would be a cost-effective alternative to the annual influenza vaccine.
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Acceptability Curves a) varying the efficacy of universal vaccine, b) varying the cost of
universal vaccine, c) varying the duration of universal vaccine protection, d) varying annual
vaccine compliance
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Table 1
Data inputs
Description (units) Distribution Mean Standard Deviation or Range Source
COSTS ($US)
 Annual vaccine Point Estimate 20 - [11,35]
  Influenza Treatment:
  Outpatient Visit
  Pediatric Outpatient Visit Point Estimate 74.90 [36]
  Adult Outpatient Visit Triangular 104.77 69.14 – 140.39 [37]
  Elderly Outpatient visit Triangular 155.92 118.39 – 193.44 [37]
  Hospitalization
 Age 1 to 4 Gamma 5992 515 [38]
 Age 5 to 9 Gamma 5761 561 [38]
 Age 10 to 14 Gamma 8735 1231 [38]
 Age 15 to 17 Gamma 6559 816 [38]
 Age 18 to 44 Gamma 6506 461 [38]
 Age 45 to 64 Gamma 7580 759 [38]
 Age 65 to 84 Gamma 7568 234 [38]
 Age 85 and Over Gamma 7698 240 [38]
 General death Triangular 6921 5191 – 9025 [39]
 Treatment of vaccine side effects Triangular 0.79 0.70 – 3.93 [11]
 Median hourly wage Point Estimate 15.57 - [35]
DURATIONS
 Work hours per day - 8 - Assumption
 Absenteeism from influenza (days) Uniform 3.2 1.5 – 4.9 [40]
 Time being sick from the flu Uniform 6 5 – 7 [41–42]
 Time after having vaccine side effects Uniform 0.75 0.5 – 1 [43]
UTILITIES (QALYs)
One year of life
 Age 0 to 17 Point Estimate 1 - [8]
 Age 18 to 64 Point Estimate 0.92 - [8]
 Age 65 and Over Point Estimate 0.84 - [8]
 Influenza with no hospitalization Triangular 0.65 0.49 – 0.81 [44–45]
 Influenza with hospitalization Triangular 0.50 0.38 – 0.63 [44,46]
 Vaccine side effects Triangular 0.95 0.71 – 1.00 [46]
PROBABILITIES
Clinical Outcomes without Vaccination
 Influenza throughout the year Triangular 0.125 0.05 – 0.2 [7]
  Outpatient Visit given influenza
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Description (units) Distribution Mean Standard Deviation or Range Source
  Age 0 to 4 Beta 0.455 0.098 [47]
 Age 5 to 17 Beta 0.318 0.061 [47]
  Age 18 to 64 Beta 0.313 0.014 [47]
  Age 65 and Over Beta 0.620 0.027 [47]
 Age 0 to 4 (High-risk) Beta 0.910 0.250 [47]
 Age 5 to 17 (High-risk) Beta 0.635 0.167 [47]
  Age 18 to 64 (High-risk) Beta 0.625 0.118 [47]
  Age 65 and Over(High-risk) Beta 0.850 0.093 [47]
  Hospitalization given influenza
  Age 0 to 4 Beta 0.0141 0.0047 [47]
  Age 5 to 17 Beta 0.0006 0.0002 [47]
  Age 18 to 49 Beta 0.0042 0.0014 [47]
  Age 50 to 64 Beta 0.0193 0.0064 [47]
  Age 65 and Over Beta 0.0421 0.0140 [47]
  Mortality given influenza
  Age 0 to 4 Beta 0.00004 0.00001 [47]
  Age 5 to 17 Point Estimate 0.00001 [47]
  Age 18 to 49 Beta 0.00009 0.00003 [47]
  Age 50 to 64 Beta 0.00134 0.00045 [47]
  Age 65 and Over Beta 0.01170 0.00390 [47]
 Vaccine efficacy Triangular 0.45 0.56 – 0.68 [7]
 Vaccine side effects Point Estimate 0.03 - [48]
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